Abstract
Amrubicin is a synthetic anthracyclin analogue that has significant activity in Japanese patients with extensive stage small cell lung cancer (ES-SCLC). There has not been significant advances made in the treatment of this disease in last several years and new therapies are desperately needed to change the natural history of this disease. Preliminary data has shown that amrubicin possesses anti-tumor activity in patients with extensive stage small cell lung cancer in the western population. Clinical trials are on going to evaluate this agent further in Europe and US. If effective, it may be an invaluable addition into the current armamentarium to treat this deadly disease. The review includes patent coverage on the treatment of small cell lung cancer.
Keywords: Amrubicin, small cell, lung cancer, chemotherapy, synthetic anthracyclin
Recent Patents on Anti-Cancer Drug Discovery
Title: Amrubicin: A Synthetic Anthracyclin Analogue in the Treatment of Extensive Stage Small Cell Lung Cancer
Volume: 4 Issue: 3
Author(s): Chirag M. Shah
Affiliation:
Keywords: Amrubicin, small cell, lung cancer, chemotherapy, synthetic anthracyclin
Abstract: Amrubicin is a synthetic anthracyclin analogue that has significant activity in Japanese patients with extensive stage small cell lung cancer (ES-SCLC). There has not been significant advances made in the treatment of this disease in last several years and new therapies are desperately needed to change the natural history of this disease. Preliminary data has shown that amrubicin possesses anti-tumor activity in patients with extensive stage small cell lung cancer in the western population. Clinical trials are on going to evaluate this agent further in Europe and US. If effective, it may be an invaluable addition into the current armamentarium to treat this deadly disease. The review includes patent coverage on the treatment of small cell lung cancer.
Export Options
About this article
Cite this article as:
Shah M. Chirag, Amrubicin: A Synthetic Anthracyclin Analogue in the Treatment of Extensive Stage Small Cell Lung Cancer, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (3) . https://dx.doi.org/10.2174/157489209789206850
DOI https://dx.doi.org/10.2174/157489209789206850 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Arsenic Trioxide and Artemisinin Act Synergistically to Kill Tumor Cells In Vitro
Anti-Cancer Agents in Medicinal Chemistry Stimuli-responsive Drug Delivery Nanosystems: From Bench to Clinic
Current Nanomedicine The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells
Current Drug Targets ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents
Current Medicinal Chemistry Drug-Lipid Membrane Interaction Mechanisms Revealed Through Molecular Simulations
Current Physical Chemistry Do We Need Full Donor Chimerism? How Alloreactive Cell Therapies without Substantial Engraftment Might Treat Hematologic Cancers
Current Drug Targets State of the Art and Perspectives in Food Allergy (Part I): Diagnosis
Current Pharmaceutical Design Human T-Cell Leukemia Virus Type 1: Transition from Latent Infection to Pathogenic Progression and Implications for Molecular Therapy
Current Cancer Therapy Reviews Angiogenesis as a therapeutic target in breast cancer
Mini-Reviews in Medicinal Chemistry Purine Analogues as Kinase Inhibitors: A Review
Recent Patents on Anti-Cancer Drug Discovery PPARγ and Its Ligands: Potential Antitumor Agents in the Digestive System
Current Stem Cell Research & Therapy Drug Disposition in Pathophysiological Conditions
Current Drug Metabolism Development of Thiazole-5-carboxylate Derivatives as Selective Inhibitors of Monoacylglycerol Lipase as Target in Cancer
Mini-Reviews in Medicinal Chemistry Induction of Humoral and Cellular Immune Responses in Mice by Multiepitope Vaccines Composing of Both T and B Lymphocyte Epitopes of MAGE-A3 which are Recombined into HBcAg
Protein & Peptide Letters Bioenergetics Pathways and Therapeutic Resistance in Gliomas: Emerging Role of Mitochondria
Current Pharmaceutical Design Cancer Cell Permeability-Glycoprotein as a Target of MDR Reverters: Possible Role of Novel Dihydropyridine Derivatives
Current Drug Targets A Systematic Analysis of Physicochemical and ADME Properties of All Small Molecule Kinase Inhibitors Approved by US FDA from January 2001 to October 2015
Current Medicinal Chemistry The Delicate Equilibrium between Oxidants and Antioxidants in Brain Glioma
Current Neuropharmacology Comprehensive DNA Methylation-transcriptome Profiles Association Analysis During the Treatment of Acute Myelocytic Leukemia
Current Pharmaceutical Design Autophagy and Cell Death in Caenorhabditis elegans
Current Pharmaceutical Design